Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- etelcalcetide
- Ospomyv (denosumab)
Interactions between your drugs
denosumab etelcalcetide
Applies to: Ospomyv (denosumab), etelcalcetide
MONITOR: Coadministration of denosumab with calcimimetic drugs such as cinacalcet and etelcalcetide, may increase the risk of hypocalcemia. This risk may be significantly higher in patients with severe renal dysfunction (creatinine clearance less than 30 mL/min) and in those receiving dialysis. The mechanism of this interaction is thought to be due to additive hypocalcemic effects.
MANAGEMENT: Caution and close monitoring of serum calcium concentrations are recommended when denosumab is used concomitantly with calcimimetic drugs such as cinacalcet and etelcalcetide. Patients and clinicians should be alert for signs and symptoms of hypocalcemia, such as numbness or tingling in the fingers, toes, or around the mouth, muscle spasms, twitches or cramps, seizures, mental status changes (confusion, irritability, depression), and irregular heartbeats.
References (2)
- Cerner Multum, Inc. "Australian Product Information."
- (2010) "Product Information. Prolia (denosumab)." Amgen USA
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Rayaldee
Rayaldee is used for hyperparathyroidism secondary to renal impairment
Parsabiv
Parsabiv is used for hyperparathyroidism secondary to renal impairment
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Sensipar
Sensipar reduces elevated levels of parathyroid hormone in people with chronic renal disease who ...
Cinacalcet
Cinacalcet systemic is used for hypercalcemia of malignancy, primary hyperparathyroidism, secondary ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.